Markets
Automarken VW, BMW, Audi, Porsche, Mercedes, Symbolfoto zum Kartellverdacht (Fotomontage)
(Bildquelle/Getty Images)

Germany’s economy falters for a second year in a row as revered car industry sputters

Once a symbol of excellence, Germany’s flagship auto industry now grapples with rising Chinese competition and slowing demand, weighing on the nation’s economy.

Hyunsoo Rim, Millie Giles

Europe’s largest economy isn’t looking healthy.

Today, Germany reported a second consecutive annual drop in GDP, with high energy costs and rising interest rates constraining growth. At the same time, its iconic automotive industry is grappling with one of its biggest threats in decades: competitors from China, which last year became the world’s largest auto exporter.

Braking bad

This week, a slew of Germany’s top carmakers reported slumping deliveries in 2024. Global sales at Volkswagen, BMW, Porsche, and Mercedes-Benz slipped 2%, 4%, 3%, and 3%, respectively, from the previous year... largely driven by even sharper respective declines in China of 10%, 13%, 28%, and 7%.

That compounds a miserable few years for many of the car industry’s most revered names, having collectively shed hundreds of billions of dollars in market cap, with Volkswagen alone down nearly €100 billion since 2021.

Germany cars market cap
Sherwood News

Indeed, Chinese customers are turning away from these luxury European electric vehicles in favor of local brands like BYD — which achieved record sales in 2024 — drawn to their relatively low prices and generous government subsidies. According to the China Passenger Car Association, Chinese automakers now dominate their home market, capturing 70% of sales — a sharp rise from 38% five years ago, when the rest was held by Western rivals. 

Meanwhile, car sales in Germany have been sliding for months, particularly in the EV segment after the government phased out subsidies at the end of 2023. According to Germany Trade and Invest, the automotive sector remains central to Germany’s economy, accounting for ~17% of the country’s exports and employing ~780,000 workers in 2023.

More Markets

See all Markets
markets

With their recent surge, Intel shares just hit their highest level since the dot-com era

Intel’s surge of nearly 60% this month has the iconic American chipmaker’s stock price approaching levels last seen during the dot-com era. Bloomberg noted that shares just touched their highest intraday level since the turn of the century:

The stock rose as much as 1.5% to $69.55, topping a peak it hit on Jan. 24, 2020. The shares are up 90% this year, after soaring 84% in 2025. Intel is now roughly 8% from its all-time closing high of $74.88, established on Aug. 31, 2000.

That’s just the most recent late-’90s-era throwback we’ve been seeing in tech shares lately. Oracle is currently pacing for its best week since late 1999.

What’s even more remarkable, however, is that Intel’s forward price-to-earnings ratio today dwarfs the premiums the market was putting on the stock during the nuttiness of the dot-com mania.

That reflects the fact that the recent run-up in Intel shares is, essentially, giving the chip giant credit for a massive turnaround that hasn’t actually happened yet.

One also might wonder if the fact that Intel is partially owned by the US government means it’s more attractive — and therefore worth a higher premium — than other chipmakers without the state imprimatur.

Still, kind of startling.

markets

Eli Lilly’s GLP-1 pill hit nearly 1,400 prescriptions in first week

Eli Lilly rose after preliminary numbers cited by Wall Street analysts showed strong uptake of its new weight-loss pill.

The FDA approved Foundayo on April 1 and shipments began on April 9. In its first week, roughly 1,400 US prescriptions were written for the drug, according to IQVIA data cited by Deustche Bank analysts in a Friday note.

Novo Nordisk, Lilly’s rival in the GLP-1 market, released its GLP-1 pill earlier this year, and early signs show that it’s expanding the market, inviting patients who were turned off by weekly injections. Novo’s pill had a stronger first week than Lilly’s, with its Wegovy pill hitting 3,071 US prescriptions in the first four days after its launch on January 5.

Lilly’s pill has an advantage over Novo’s, which is that it can be taken at any time of day, with or without food. Lilly disclosed in a February regulatory filing that it had $1.5 billion worth of prelaunch inventory ready ahead of the FDA approval — which is about as much as analysts polled by FactSet expect it to sell this year.

Novo Nordisk, Lilly’s rival in the GLP-1 market, released its GLP-1 pill earlier this year, and early signs show that it’s expanding the market, inviting patients who were turned off by weekly injections. Novo’s pill had a stronger first week than Lilly’s, with its Wegovy pill hitting 3,071 US prescriptions in the first four days after its launch on January 5.

Lilly’s pill has an advantage over Novo’s, which is that it can be taken at any time of day, with or without food. Lilly disclosed in a February regulatory filing that it had $1.5 billion worth of prelaunch inventory ready ahead of the FDA approval — which is about as much as analysts polled by FactSet expect it to sell this year.

markets

Critical Metals jumps after Greenland’s government approves CRML to take majority control of the Tanbreez mining project

Critical Metals is up more than 25% in premarket trading on Friday after the critical mining company announced that it now owns 92.5% of the Tanbreez rare earth deposit following an approval from the government of Greenland.

With that latest government support, Critical Minerals added an additional 50.5% stake to its ownership, reportedly acquired from Rimbal Pty Ltd, per Bloomberg News. With access to eight heavy rare earth elements often used in consumer electronics and defense, the site is one of the world’s largest undeveloped rare earth deposits and a key source of rare earth supply outside of China, according to the company.

In Critical Metals’ press release, Chairman Tony Sage commented that the approval “removes the most significant structural overhang on the project and provides the clarity to advance Tanbreez to production with confidence,” especially as Tanbreez’s location offers a significant logistical advantage through its year-round direct shipping access, compared to rival projects.

With 92.5% of the project now vested in Critical Metals Corp., and the remainder owned by European Lithium Ltd., CRML now has full control of the project and is seeking to accelerate development there, with plans for a new international airport and a 150-tonne bulk sample program, which is slated for June 2026.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.